Drug resistance is a major obstacle in the field of pre-clinical and clinical therapeutics. The
development of novel technologies and targeted therapies have yielded new modalities to …

Over the past ten years, proteasome inhibition has emerged as an effective therapeutic
strategy for treating multiple myeloma (MM) and some lymphomas. In 2003, Bortezomib …

Proteasome inhibitors (PIs), such as bortezomib, carfilzomib or NPI-0052, have excellent
clinical activity in patients with multiple myeloma and mantle cell lymphoma, and they are …

Proteasome inhibition with bortezomib is a validated approach to the treatment of multiple
myeloma, but drug resistance often emerges and limits its utility in the retreatment setting. To …

The proteasome is the central component of the main cellular protein degradation pathway.
During the past four decades, the critical function of the proteasome in numerous …

Multiple molecular, cellular, micro-environmental and systemic causes of anticancer drug
resistance have been identified during the last 25 years. At the same time, genome-wide …

The proteasome inhibitor, bortezomib, a boronic dipeptide which reversibly inhibit the
chymotrypsin-like activity at the β5-subunit of proteasome (PSMB5), has marked efficacy …

Determining mechanisms of drug action in human cells remains a major challenge. Here we
describe an approach in which multiple-drug-resistant clones are isolated and transcriptome …

The ubiquitin/26S proteasome system (UPS) plays a central role in plant protein
degradation. Over the past few years, the importance of this pathway in plant–pathogen …

Resistance towards the proteasome inhibitor bortezomib is poorly understood. We adapted
the HL-60, ARH-77 and AMO-1 cell lines (myeloid leukemia, plasmocytoid lymphoma …